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Abstract
Colorectal cancer (CRC) is characterized by complex interplay between macroenvironmental factors and tumour microenvironment,
leading to variable outcomes in CRC patients. To date, there is still a need to identify macroenvironment/microenvironment factors that
could define subgroup of patients that would benefit from specific anti-cancer treatment in order to improve patient selection for
individualized targeted-based therapy. Aim of this study was to evaluate associations between metabolic parameters and KRAS status
in metastatic CRC (mCRC) according to a new tumour site classification. Retrospective data were extracted from a total of 201 patients
diagnosed with mCRC between 2012 and 2017 extracted from an established CRC database at our tertiary institute. Clinical-pathological
data, including age, gender, BMI, hypertension, diabetes, pre-CRC diagnosis serum lipid levels and KRAS status were recorded.
Categorical characteristics were compared using chi-squared test. Continuous characteristics were compared usingMann-Whitney U test.
Log rank test was used to compare hazards for survival. In all comparisons, a two-sided P value <0.05 was considered statistically
significant. Out of 201 patients, 170 patientswith complete serum lipid profilewere included in the analysis. In recto-sigmoid cancers there
was a statistically significant association between high cholesterol:high-density lipoprotein (chol:HDL) ratio and KRAS mutation (OR
2.69, 95%CI 1.1–6.4, p= 0,02). In non recto-sigmoid cancers, high cholesterol was associated with KRASWT (OR 0.39, CI 0.15–0.97,
p= 0.04). In 22 patients with KRAS mutated recto-sigmoid cancer stage IV at diagnosis normal chol:HDL ratio was associated with a
trend to better survival (p= 0.06). High chol:HDL ratiowas significantly associatedwithKRASmutatedmetastatic recto-sigmoid cancers.
A subgroup of mCRC patients with KRAS mutated recto-sigmoid cancer may benefit from optimal lipid lowering treatment.
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Introduction
Colorectal cancer (CRC) is a heterogeneous disease character-
ized by complex interplay between genetic and epigenetic
modifications within tumour and environmental factors.
Biologic modifications also occur in the macroscopically nor-
mal colonic mucosa adjacent to the neoplastic lesion, known
as field cancerization [1]. Obesity and metabolic syndrome
(MetS) are established risk factors of CRC incidence and mor-
tality [2, 3]. Recently, the role of dysfunctional adipose tissue
in cancer progression has emerged [4, 5]. Nevertheless, inter-
actions between genetic, epigenetic and environmental factors
in CRC risk and carcinogenesis remain poorly characterized.
Despite recent advances in cancer therapies, CRC remains
the second cause of cancer death in the Western world [6]. To
date, there is still a need to define subgroup of patients that
would benefit from specific anti-cancer treatment in order to
improve patient selection for individualized targeted-based
therapy.
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Around 20% of CRC patients present with metastatic
disease and approximately 25%–30% of patients with
CRC stage II/III develop recurrence within 5 years of
curative intent surgery [7]. Current predictive and prog-
nostic systems, consisting in tumour, node, metastasis
(TNM) classification combined with molecular bio-
markers lack accuracy. The most frequent point mutations
in KRAS codon 12 and 13 have been recognized as pre-
dictive markers of resistance to anti-epidermal growth fac-
tor receptor (EGFR) targeted therapies, cetuximab and
panitumumab, as adjuvant treatment in advanced disease
in combination with cytotoxic chemotherapy [8].
However, only 40–60% of patients with wild type
KRAS tumours respond to anti EGFR therapy. A new
classification has been reported for clinical classification
and subtype-based targeted therapies based on four con-
sensus molecular subtypes (CSM), considered a more ro-
bust classification than the current TNM system [9].
Primary tumour location (right sided versus left sided)
has recently emerged as prognostic and predictive factor
in patients with KRAS wild type mCRC treated with che-
motherapy and EGFR directed antibodies, with worse sur-
vival in patients with right sided colon cancer and KRAS
wild type [10, 11], whilst KRAS mutations have been
associated with worse survival only in left sided cancer
[12]. However, current left/right sided colon cancer clas-
sification is still debated. Reliable prognostic and predic-
tive biomarkers to guide treatment in patients with stage
IV CRC are needed.
Traditional epidemiologic research has focused on risk fac-
tors associated with CRC without considering CRC genetic
and epigenetic heterogeneity. A new area of research termed
“molecular pathologic epidemiology” has detected epigenetic
modifications associated with obesity, providing insights into
the relationship between obesity and molecular variants in
CRC [13]. Associations between environmental factors and
KRAS status have not been extensively investigated. Only a
few studies have reported inconsistent findings regarding as-
sociations between BMI/metabolic parameters and KRAS sta-
tus [14–18].
In the present study, we evaluated associations between
clinical, metabolic and molecular parameters (KRAS status)
in metastatic CRC (mCRC) patients according to a novel clas-
sification for primary tumour location. There is recent evi-
dence suggesting similar biologic features in sigmoid colon
and rectal cancers [19, 20]. We clustered CRCs according to
primary location at rectum and sigmoid colon (recto-sigmoid
cancers) and at ascending, transverse and proximal descend-
ing colon (non recto-sigmoid cancers).
Identifying associations between macro-environmental
features and CRC molecular profile is critical to identify ad-
junctive prognostic and predictivemarkers of response to ther-
apy and potential new therapeutic targets.
Methods
Research Governance approval was obtained from Research
and Development department at University Hospitals
Coventry and Warwickshire.
Study Population
All mCRC patients diagnosed between January 2012 and
July 2017 at Univers i ty Hospita ls Coventry and
Warwickshire were retrieved from a CRC database. Patients
with histologically confirmed diagnosis of CRC and available
KRAS status on histology report were included in this study.
Clinical-pathological data including age, gender, BMI, hyper-
tension, diabetes and lipid profile consisting in pre CRC diag-
nosis median values of total serum cholesterol, triglyceride,
high-density lipoprotein cholesterol (HDL-chol),
cholesterol:high-density lipoprotein (chol:HDL) ratio, low-
density lipoprotein-cholesterol (LDL-chol) were retrospec-
tively collected from clinical records. Patients were consid-
ered with raised lipid profile according to the following cut-
off values: cholesterol ≥5 mmol/l, chol:HDL ratio ≥ 3.5, LDL-
chol ≥1.8 mmol/l, HDL-chol <1.03 mmol/l in men and <
1.29 mmol/l in women, triglycerides ≥1.7 mmol/l. Cut off
value for HbA1c was 48 mmol/mol, which is the cut off point
for diagnosis of diabetes. Pathological data including CRC
anatomic location, stage and KRAS status were also retrieved.
KRAS mutation analysis was performed at University
Hospitals Birmingham. DNAwas extracted from paraffin em-
bedded sections. KRAS mutations in codon 12, 13 and 61
were analyzed employing KRAS Pyro Kit, according to the
manufacturer protocol (Quiagen, Germany). KRASmutations
in codon 146 were analyzed employing RAS extension Pyro
Kit, according to the manufacturer protocol (Quiagen,
Germany).
CRC Classification
Tumours were classified as non recto-sigmoid cancers if lo-
cated at ascending colon, transverse colon and proximal de-
scending colon, and recto-sigmoid cancers if located at rectum
and sigmoid colon. All CRCs were classified as KRAS mu-
tated or wild type (WT). Cancer stage was classified into II, III
and IV according to the TNM staging system of the American
Joint Committee on Cancer (AJCC) 7th Edition [21].
Patient Classification
Patients were classified in relation to body mass index (BMI)
in three groups: normal weight patients (BMI ≥18.5 ≤ 24.9),
overweight (BMI ≥25 ≤ 29.9), obese patients (BMI ≥30). For
Asian patients we employed cut off for obesity of ≥27.5 ac-
cording to WHO Expert Consultation [22].
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Hypertension was defined as use of any antihypertensive
medication. Diabetes mellitus was defined as use of any dia-
betes medication.
Patients were classified in two groups according to pres-
ence or absence of MetS. Patients were considered to have
MetS when they presented central obesity and two or more
criteria according to the International Diabetes Federation
criteria (IDF) [23] (Supplementary File Table 1).
Statistical Analysis
IBM SPSS v 24.0 /2016 was used for statistical analysis.
Categorical characteristics were compared using the chi-
squared test or Fisher’s exact test, as appropriate. Mann-
Whitney U test was used to compare continuous characteris-
tics between KRASmutated and wild type groups. Means and
standard deviations (SD) of continuous characteristics for
KRAS mutated and WT groups were reported. The odds ratio
(OR) (mutated to WT) comparing the presence of character-
istic such as raised cholesterol and 95% confidence intervals
(CI) were reported. For the analysis including multiple char-
acteristics, a multivariable logistic regression model was used.
Patient survival curves were plotted using the Kaplan-Meier
method. Log rank test was used to compare hazards of death
between patients with high and low chol:HDL ratio in CRC
stage III and stage IV at diagnosis according to primary tu-
mour location. A two-sided P value <0.05 was considered
statistically significant.
Results
Out of approximately 1000 CRC patients, 201 patients had
histological diagnosis of CRC with KRAS status available
on histology report and partial lipid profile (total serum cho-
lesterol, chol:HDL ratio and LDL-cholesterol). Out of 201
patients, 170 had complete lipid profile (total serum cholester-
ol, triglyceride, HDL-chol, chol:HDL ratio and LDL-choles-
terol). Out of 170 patients, 68 (40%) were females and 102
(60%) were males. The median age at diagnosis was 66 years
(SD11.30). 28 patients (16.47%) had cancer located at cae-
cum, 23 (13.5%) at ascending colon, 7 (4.1%) at hepatic flex-
ure, 11 (6.5%) at transverse colon, 4 (2.3%) at splenic flexure,
4 (2.3%) at descending colon, 30 (17.6%) at sigmoid colon, 63
(37%) at rectum. 99 patients (58.23%) exhibited KRAS mu-
tations and 71 (41.76%) KRAS WT. 50% of recto-sigmoid
cancers exhibited KRAS mutation. Equally, 50% of non
recto-sigmoid cancers exhibited KRAS mutation.
Demographic characteristics of the cohort are represented in
Table 1.
The results revealed a statistically significant association
between KRAS status according to primary cancer location
and each of chol:HDL ratio and serum cholesterol (Table 2).
For recto-sigmoid cancers, there was a statistically significant
association between high chol:HDL ratio and KRASmutation
(OR 2.69, 95% CI 1.1–6.4, p = 0,02). In non recto-sigmoid
cancers, high cholesterol was significantly associated with
KRAS WT (OR 0.39, CI 0.15–0.97, p = 0.04), whilst there
was a borderline association between MetS and KRAS muta-
tion (OR 2.78, 95% CI 0.99–7.82, p = 0.05). There was no
statistically significant association between BMI categories,
hypertension, diabetes, statin use and KRAS status in any
tumour location. Frommultivariable binary logistic regression
chol:HDL ratio was the only significant predictor of KRAS
status in recto-sigmoid cancers (OR 4.005, CI 1.223–13.116,
p = 0.02). In non recto-sigmoid cancers triglycerides and
HDL-chol were both significant predictors of KRAS status
(OR 4.449, 95% CI 1.071–18.485, p = 0.04; OR 7.905, CI
1.121–55.744, p = 0.04, respectively) (Supplementary File
Table 2). In multivariable analysis in colon cancers classified
as right sided and left sided, we did not identify any statisti-
cally significant association between serum lipid profile and
KRAS status. However, in right sided cancers MetS, defined
with BMI ≥29 as cut-off of high waist circumference, was
significantly associated with KRAS status (OR 6.000, 95%
CI 1.501–23.991, p = 0.007) (Supplementary File Table 3).
Associations between serum lipid profile and KRAS status
were verified in a larger cohort of 201 patients with total
cholesterol, chol:HDL ratio and HDL-cholesterol available.
Results confirmed a significant association between high
chol:HDL ratio and KRAS mutation in recto-sigmoid cancers
(OR 3, CI 1.3–6.8, p = 0.009). In non recto-sigmoid cancers
high cholesterol was significantly associated with KRAS WT
(OR 0.3, CI 0.14–0.84, p = 0.01).
Among 201 patients KRAS mutations in codon 12 were
the most frequently observed (31.3%). Codon 12 exhibited 5
mutational types and the most frequently observed was G12A
both in recto-sigmoid and non recto-sigmoid cancers (31.1%
and 31.6% respectively) (Table 3). We did not observe signif-
icant association between KRAS genotype and lipid profile or
tumour location.
Survival analysis was performed in 22 patients with KRAS
mutated recto-sigmoid cancer stage IV at diagnosis. Results
revealed a trend towards better survival in patients with low
chol:HDL ratio compared to patients with high chol:HDL
ratio (p = 0.06) (Fig. 1). No difference in survival was ob-
served in patients with KRAS WT CRC for each tumour lo-
cation (Fig. 2).
In 13 patients with KRAS mutated recto-sigmoid cancer
stage III at diagnosis, we observed better survival in patients
with high chol:HDL ratio (p = 0.05) (Fig. 3). We did not ob-
serve differences in 16 patients with KRAS mutated non
recto-sigmoid cancer stage III at diagnosis according to
chol:HDL ratio.
Out of 85 CRC patients stage III at diagnosis, 34 (40%)
patients were on statin treatment. Out of 72 CRC patients
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stage IV at diagnosis, 31 (43.1%) patients were on statin treat-
ment. We performed survival analysis in patients with stage
III and stage IV CRC at diagnosis according to tumour loca-
tion and statin treatment. No statistical difference in survival
was observed.
Discussion
Previous studies evaluating association between obesity/MetS
and KRAS status have yielded inconclusive results [14–18].
In this study we investigated associations between serum lipid
profile, BMI and metabolic factors with KRAS status accord-
ing to primary tumour location. The present study differs from
previous studies in the classification of primary tumour
location, traditionally classified as right sided, left sided and
rectal cancer. We employed a new classification of recto-
sigmoid versus non recto-sigmoid cancers. Results of this ex-
ploratory study revealed association between lipid profile and
KRAS status according to primary tumour location. In both
univariable and multivariable analysis, there was a statistically
significant association between chol:HDL ratio and KRAS
mutation in recto-sigmoid cancers (p = 0.02). KRAS codon
13 mutations have been found to be significantly associated
with high plasma cholesterol [24]. In this study we did not
identify any associations between serum lipid profile and one
specific KRAS mutation, likely related to the small sample
size. Results of the present study suggest that dysregulated
serum lipid profile may be implicated in KRAS mutated sig-
naling pathways in a subset of KRAS mutated metastatic
Table 1 Demographic
characteristics of the cohort of
patients with mCRC (n = 170)
Characteristic All patients KRAS mutation
Age at diagnosis (years), mean ± SD 66.28 ± 11.3
Gender
Male, n (%) 102 (60)
Female, n (%) 68 (40)
Ethnicity
Caucasian, n (%) 157 (92.3)
Non-caucasian, n (%) 13 (18.5)
BMI (kg/m2), mean ± SD 27.7 (6.0)
Overweight/obese, n (%) 119 (70)
Metabolic Syndrome according to IDF definition
Non-sigmoid rectal cancers, n (%) 18 (10.5)
Sigmoid rectal cancers, n (%) 22 (12.9)
Metabolic syndrome according to modified
IDF definition (central obesity assumed if BMI ≥29)
Non-sigmoid rectal cancers, n (%) 20 (11.7)
Sigmoid rectal cancers, n (%) 24 (14.1)
Diabetes, n (%)
Dyslipidaemia, n (%) 38 (22.3)
Dyslipidaemia in treatment with statins, n (%) 81 (47.6)
Hypertension, n (%) 74 (91.3)
Cancer sub-location 110 (64.7)
Caecum, n (%) 28 (16.4) 19 (11.2)
Ascending colon, n (%) 23 (13.) 10 (5.8)
Hepatic flexure, n (%) 7 (4.1) 1 (0.5)
Transverse colon, n (%) 11 (6.5) 2 (1.2)
Splenic flexure, n (%) 4 (2.3) 2 (1.2)
Descending colon, n (%) 4 (2.3) 2 (1.2)
Sigmoid colon, n (%) 30 (17.6) 9 (5.3)
Rectum, n (%) 63 (17) 28 (16.5)
Definition of primary tumour location
Non-sigmoid rectal cancers, n (%) 78 (45.8)
Sigmoid rectal cancers, n (%) 92 (54.1)
Stage at diagnosis
II, n (%) 14 (8.2)
III, n (%) 75 (44.1)
IV, n (%) 81 (47.6)
KRAS status
Wild type, n (%) 99 (58.2)
Mutated, n (%) 71 (41.7)
mCRCmetastatic colorectal cancer, SD standard deviation, IDF international diabetes federation, BMI body mass
index, KRAS Kirsten rat sarcoma viral oncogene
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recto-sigmoid cancers, thus leading to the deduction that lipid
lowering treatment may be effective in such subset of mCRC
patients.
Clinical studies on the effectiveness of statin use after CRC
diagnosis have yielded inconclusive results [25–28].A recent
systematic review and meta-analysis evaluating statin use and
mortality in CRC patients has highlighted that statin use pre
and post CRC diagnosis improved overall and cancer specific
survival in CRC patients. However, no statistical difference in
all cause mortality in post-CRC diagnosis statin users in sub-
group analysis by KRAS mutation status was identified,
although there was a trend towards a reduction in all cause
mortality in KRAS mutated CRC patients in treatment with
statins after CRC diagnosis [29]. Therefore, there is an urgent
clinical need to identify an appropriate subgroup of CRC pa-
tients that would benefit from statin treatment in association
with adjuvant chemotherapy.
Retrospective cohort studies have shown that statin use in
rectal cancer patients undergoing neoadjuvant chemoradio-
therapy appears to confer higher pathological regression rates
[30, 31]. Results of the present study have identified a sub-
group of patients with KRASmutated mCRC located at recto-
Table 3 KRAS codon, nucleotide change and amino acid change in 201mCRC according to tumour location as recto-sigmoid cancer versus non recto-
sigmoid cancer
KRAS codon Nucleotide change Amino acid change n (%) among
201 mCRC cases
n (%) among
106 recto-sigmoid
cancer cases
n (%) among
95 non recto-sigmoid
cancer cases
12 c.34G >A G12S 3 (1.5) 1 (1) 2 (2)
12 c.35G > T G12V 17 (8.5) 8 (7.5) 9 (9.5)
12 c.35G >A G12D 6 (3) 3 (2.8) 3 (3)
12 c.34G > T G12C 8 (4) 4 (3.7) 4 (4)
c.38G >A
12 c.35G > C G12A 29 (14) 17 (16) 12 (12.6)
c.35G >A
13 c.38G >A G13D 2 (1) – 2 (2)
13 c.38G >A G13A 9 (4.5) 5 (4.7) 4 (4)
c.37G > T
61 c.181C >A Q61K 3 (1.5) – 3 (3)
c.183A > C Q61H
146 c.436G >A p.A146T 4 (2) 4 (3.7) –
c.436G > C p.A146P
c.437C > T p.A146P
mCRC: metastatic colorectal cancer
Fig. 1 Survival analysis. Kaplan Meier survival curves of 22 patients
with KRAS mutated recto-sigmoid cancer stage IV at diagnosis stratified
by chol:HDL ratio (a); survival curves of 19 patients with KRASmutated
non recto-sigmoid cancers stage IV at diagnosis stratified by chol:HDL
ratio (b). Patients with KRAS mutated recto-sigmoid cancer with normal
chol:HDL ratio exhibited a better survival compared to patients with high
chol:HDL ratio, not observed in non recto-sigmoid cancer
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sigmoid colon as a candidate subgroup of patients that may
benefit from statin treatment in association with adjuvant
chemotherapy.
Studies evaluating the role of dyslipidemia in CRC patients
outcomes have yielded conflicting results [32, 33], with some
studies highlighting better survival with high serum
cholesterol.
In the present study survival analysis in 22 patients with
KRAS mutated recto-sigmoid cancer stage IV at diagnosis
revealed a trend towards better survival in patients with low
chol:HDL ratio compared to patients with high chol:HDL
ratio (p = 0.06). In a subgroup analysis comparing mCRC pa-
tients in treatment with statins versus non statin users stratified
by tumour location (recto-sigmoid versus non recto-sigmoid
colon, right colon versus left colon, colon versus rectum) and
KRAS status, we did not observe improved survival in CRC
patients in treatment with statins. It is noteworthy that mean
cholesterol and chol:HDL ratio in patients with recto-sigmoid
cancers treated with statins were above therapeutic target
levels (5.1 mmol/l and 3.6 respectively), suggesting that sub-
optimal treatment of dyslipidemia may have been responsible
of the lack of expected improved survival observed in such
patients in treatment with statins (Supplementary File
Table 4). It is plausible that the effect of statins on a subset
of CRC patients outcomes is related to its lipid lowering
effect.
In patients with KRAS mutated recto-sigmoid cancer stage
III at diagnosis, high chol:HDL ratio was associated with bet-
ter survival. These results are in line with previous studies
demonstrating that dyslipidemia resulted in improved survival
in patients with non-metastatic CRC [34]. The mechanisms
underlying the protective effect of dyslipidemia in non-mCRC
Fig. 3 Survival analysis. Kaplan Meier survival curves in 13 patients
with KRAS mutated recto-sigmoid cancer stage III at diagnosis stratified
by chol:HDL ratio (a); Kaplan Meier survival curves in 16 patients with
KRAS mutated non recto-sigmoid cancer stage III at diagnosis (b).
Results show better survival in KRAS mutated recto-sigmoid cancer pa-
tients with high chol:HDL ratio compared to normal chol:HDL ratio
Fig. 2 Survival analysis. Kaplan Meier survival curves of 26 patients
with KRAS WT recto-sigmoid cancer stage IV at diagnosis stratified
according to chol:HDL (a); Kaplan Meier survival curves of 26 patients
with KRASWT non recto-sigmoid cancer stage IV at diagnosis stratified
according to chol:HDL (b). Results revealed no difference in survival in
patients with KRAS WT cancer stratified by chol:HDL ratio for both
tumour locations
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remain elusive. Serum cholesterol levels have been demon-
strated to decline prior to diagnosis of CRC [35], likely related
to actively proliferating and aggressive cancer cells, which
utilize host lipids for proliferation and survival. High serum
lipid levels, in the setting of non-mCRC, may reflect a less
aggressive cancer phenotype.
In univariable analysis, high serum cholesterol level was as-
sociated with KRAS WT in non recto-sigmoid cancers (p =
0.04). Given the retrospective nature of this study waist circum-
ference could not be measured, resulting in likely underestima-
tion of the MetS group. Therefore, in order to increase patient
group with MetS, we reduced BMI cut off to ≥29, resulting in 2
more patients with MetS for each tumour location. Employing a
lower BMI cut off for obesity at ≥29 as assumption of high waist
circumference, there was a borderline association between MetS
and KRAS mutation in non recto-sigmoid cancers (p = 0.05),
whilst no significant association was identified employing cut
off ≥30 as per IDF guidelines.
The prognostic and predictive role of primary tumour loca-
tion classified as right sided versus left sided colon cancers has
recently been highlighted. In the present study, in multivari-
able analysis in colon cancers classified as right sided and left
sided, we did not identify any statistically significant associa-
tion between serum lipid profile and KRAS status. However,
in right sided cancers MetS, defined with BMI ≥29 as cut-off
of high waist circumference, was significantly associated with
KRAS status (OR 6.000, 95% CI 1.501–23.991, p = 0.007).
In-vitro studies have suggested that statins may interfere with
KRAS downstream signaling pathways via inhibition of KRAS
prenylation essential for membrane translocation of KRAS and
activation of signaling pathways. Experimental data has
highlighted that statins can reverse cetuximab resistance in
KRAS mutant CRC [36] and enhance chemosensitivity to 5-
fluorouracil inducing epigenetic reprogramming [37]. In-vitro
studies have demonstrated that targeting cholesterol synthesis
results in sensitizing resistant cancer cells to EGFR inhibitors
[38, 39]. However, one randomized clinical trial has failed to
demonstrate the efficacy of statins in KRAS mutated mCRC
patients in treatment with Cetuximab [40]. Results of this study
raise the hypothesis of a possible enhancing chemosensitivity
effect of statins in a subset of KRAS mutated mCRC patients
with recto-sigmoid cancer.
Lipids are an essential component of plasma membrane in-
volved in cancer cell signaling and cancer metabolism and their
role in KRAS-mediated cancers is emerging [41, 42]. KRAS pro-
teins and signaling pathways have received broad attention for
anticancer therapy. Several therapeutic approaches targeting onco-
genic RAS have been explored, including inhibition of enzymes
involved in post-translational modification of RAS proteins [43],
siRNA for silencing KRAS isoforms [44] amongst others.
Nevertheless, to date there are no effective anti KRAS therapies.
KRAS proteins assemble on the plasma membrane in
nanoclusters [45–47], essential for effector binding and activation
of MAPK pathway [48] and phosphatidyl inositol 3-kinase
(PI3K)/AKT/mTOR signaling pathway [49], resulting in cell
proliferation and survival. Cancers exhibit a reprogrammed met-
abolic phenotype to supply high energetic demands and biosyn-
thetic pathways, consisting of increased avidity for glucose, ac-
tivation of aerobic glycolysis, reprogramming of amino-acid me-
tabolism and altered lipid metabolism and fatty acid oxidation
Fig. 4 Representation of KRAS
nanoclusters in plasma membrane
and signaling pathways. GTP:
guanosin 5′-triphosphate; MAPK:
Mitogen-activated protein kinase;
RAF: Rapidly Accelerated
Fibrosarcoma; MEK: mitogen-
activated protein kinase kinase;
ERK: Extracellular signal-
Regulated Kinase; PI3K:
Phosphoinositide 3-kinase; AKT:
serine/threonine protein kinase;
mTOR: mammalian target of
rapamycin
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[50, 51]. Mutated KRAS has recently emerged as a key driver
gene of metabolic reprogramming [41, 42, 52–54]. Therapies
targeting metabolic reprogramming have recently been sug-
gested with variable outcomes depending on local environment,
highlighting that the microenvironment plays a key role in
KRAS mutant metabolic remodelling [55]. Figure 4 depicts
KRAS distribution in the plasma membrane and downstream
effects.
Mutant KRAS driven cancers have been implicated in cell
signaling and tumour metabolic remodelling in an environ-
ment dependent manner, mediated through cross-talk with
surrounding stromal compartment [56] and differing accord-
ing to tissue of origin [57]. According to the results of the
present study, we could postulate that dysregulation of multi-
ple systemic metabolic factors is implicated in KRAS-driven
metabolic reprogramming in non recto-sigmoid cancers,
whilst in cancers with a distal location serum dyslipidemia
may facilitate KRAS related cancer progression. The differ-
ence between the two subsites may reflect diversities in tu-
mour microenvironment (TME), with a TME in distal colon
favoring KRAS related tumor progression in patients with
serum dyslipidemia. In vitro studies employing three-
dimensional (3D) cancer organoid models derived from
recto-sigmoid cancers and non recto-sigmoid cancers are war-
ranted to understand the role of lipids in KRAS mutated sig-
naling pathways and cancer metabolism within the 2 different
tumour locations. These in vitro organ-like cultures reproduce
intestinal tissue microenvironment proteins and lipids [58],
allowing to understand interplay between tumour cells and
microenvironment.
CRC is a heterogeneous disease and it is plausible that the
effect of statins may differ according to tumour location and
molecular subtype. Retrospective studies and prospective
clinical trials evaluating the effect of statins on patients strat-
ified by tumour location and KRAS status are lacking.
Therefore, a new approach in the design of clinical trials is
urgently needed taking into consideration primary tumour lo-
cation. According to the results of this study, we suggest clus-
tering together rectal and sigmoid cancers versus non recto-
sigmoid cancers stratified by KRAS status.
Clinical implications of the results of this study are multi-
ple. Firstly, it lays the foundations to improve colon cancer
treatment through optimal lipid lowering treatment in associ-
ation with adjuvant chemotherapy in a subgroup of patients
with KRAS mutated metastatic recto-sigmoid cancer.
Secondly, it offers insights on possible prognostic and pre-
dictive biomarkers in mCRC. Chol:HDL ratio could represent
a valuable adjunctive metabolic prognostic and predictive bio-
marker in a subset of KRAS mutated mCRCs located at sig-
moid-rectum. In this study in non recto-sigmoid cancers high
serum cholesterol was associated with KRASWT. Evaluation
of high serum cholesterol as a predictive biomarker of re-
sponse to anti EGFR therapies in non recto-sigmoid cancers
in retrospective/prospective studies may warrant further
evaluation.
Finally, serum lipid profile could be a valuable risk strati-
fication tool to help identify high risk individuals to be imple-
mented in current CRC screening and surveillance strategies.
This hypothesis needs to be explored in large multicentre
studies.
A limitation of this study is the relatively small sample size.
Precise estimates were not feasible, such as high odds ratio
and wide confidence intervals that include the one (the null
hypothesis value) observed when evaluating associations be-
tween MetS and KRAS status in non recto-sigmoid cancers.
In conclusion, chol:HDL ratio was significantly associated
with KRAS mutation in metastatic recto-sigmoid cancers.
Lipid lowering treatment may be effective in a subset of pa-
tients with KRAS mutated metastatic recto-sigmoid cancer.
Results of this study need to be validated in a larger
multicentre cohort. Randomized controlled trials employing
our novel tumour location classification are warranted to in-
vestigate the effectiveness of statins in a subgroup of mCRC
patients.
Results of this study could lead to improved individualized
screening, surveillance and treatment strategies.
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